When should we order a next generation sequencing test in a patient with cancer?
Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although n...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537020302315 |
| _version_ | 1819089414488326144 |
|---|---|
| author | Ramon Colomer Rebeca Mondejar Nuria Romero-Laorden Arantzazu Alfranca Francisco Sanchez-Madrid Miguel Quintela-Fandino |
| author_facet | Ramon Colomer Rebeca Mondejar Nuria Romero-Laorden Arantzazu Alfranca Francisco Sanchez-Madrid Miguel Quintela-Fandino |
| author_sort | Ramon Colomer |
| collection | DOAJ |
| description | Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice. |
| first_indexed | 2024-12-21T22:07:33Z |
| format | Article |
| id | doaj.art-e1f26395b6474bfa9841102a9061406a |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-12-21T22:07:33Z |
| publishDate | 2020-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-e1f26395b6474bfa9841102a9061406a2022-12-21T18:48:40ZengElsevierEClinicalMedicine2589-53702020-08-0125100487When should we order a next generation sequencing test in a patient with cancer?Ramon Colomer0Rebeca Mondejar1Nuria Romero-Laorden2Arantzazu Alfranca3Francisco Sanchez-Madrid4Miguel Quintela-Fandino5Departament of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Medical Oncology Division, Hospital Universitario La Princesa, Madrid, Spain; Endowed Chair of Personalised Precision Medicine, Universidad Autónoma de Madrid (UAM)-Fundación Instituto Roche, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Corresponding author.Departament of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Medical Oncology Division, Hospital Universitario La Princesa, Madrid, Spain; Endowed Chair of Personalised Precision Medicine, Universidad Autónoma de Madrid (UAM)-Fundación Instituto Roche, SpainMedical Oncology Division, Hospital Universitario La Princesa, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, SpainImmunology Division, Hospital Universitario La Princesa, Madrid, SpainDepartament of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Endowed Chair of Personalised Precision Medicine, Universidad Autónoma de Madrid (UAM)-Fundación Instituto Roche, Spain; Immunology Division, Hospital Universitario La Princesa, Madrid, SpainDepartament of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Medical Oncology Division, Hospital Universitario Quirón, Pozuelo de Alarcón – Madrid, SpainTechnical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.http://www.sciencedirect.com/science/article/pii/S2589537020302315Precision oncologyPersonalised medicineNext generation sequencingCancer GenomicsCancer TherapyTargeted therapy |
| spellingShingle | Ramon Colomer Rebeca Mondejar Nuria Romero-Laorden Arantzazu Alfranca Francisco Sanchez-Madrid Miguel Quintela-Fandino When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine Precision oncology Personalised medicine Next generation sequencing Cancer Genomics Cancer Therapy Targeted therapy |
| title | When should we order a next generation sequencing test in a patient with cancer? |
| title_full | When should we order a next generation sequencing test in a patient with cancer? |
| title_fullStr | When should we order a next generation sequencing test in a patient with cancer? |
| title_full_unstemmed | When should we order a next generation sequencing test in a patient with cancer? |
| title_short | When should we order a next generation sequencing test in a patient with cancer? |
| title_sort | when should we order a next generation sequencing test in a patient with cancer |
| topic | Precision oncology Personalised medicine Next generation sequencing Cancer Genomics Cancer Therapy Targeted therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2589537020302315 |
| work_keys_str_mv | AT ramoncolomer whenshouldweorderanextgenerationsequencingtestinapatientwithcancer AT rebecamondejar whenshouldweorderanextgenerationsequencingtestinapatientwithcancer AT nuriaromerolaorden whenshouldweorderanextgenerationsequencingtestinapatientwithcancer AT arantzazualfranca whenshouldweorderanextgenerationsequencingtestinapatientwithcancer AT franciscosanchezmadrid whenshouldweorderanextgenerationsequencingtestinapatientwithcancer AT miguelquintelafandino whenshouldweorderanextgenerationsequencingtestinapatientwithcancer |